References
- Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA. 2003;100(3):928–933. doi: 10.1073/pnas.0335507100
- Seidah NG, Prat A. The multifaceted biology of PCSK9. Endocr Rev. 2022 May 12;43(3):558–582. doi: 10.1210/endrev/bnab035
- Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–156. doi: 10.1038/ng1161
- Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005 Feb;37(2):161–165. doi: 10.1038/ng1509
- Cohen JC, Boerwinkle E, Mosley TH Jr., et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264–1272. doi: 10.1056/NEJMoa054013
- Hooper AJ, Marais AD, Tanyanyiwa DM, et al. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis. 2007 Aug;193(2):445–448. doi: 10.1016/j.atherosclerosis.2006.08.039
- Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006 Sep;79(3):514–523. doi: 10.1086/507488
- Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018 [2019 Jun 18];139(25):e1082–e1143.
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. [2017 May 4];376(18):1713–1722. doi: 10.1056/NEJMoa1615664
- Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. [2018 Nov 29];379(22):2097–2107. doi: 10.1056/NEJMoa1801174
- Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. [2020 Apr 16];382(16):1507–1519. doi: 10.1056/NEJMoa1912387
- Coppinger C, Movahed MR, Azemawah V, et al. A comprehensive review of PCSK9 Inhibitors. J Cardiovasc Pharmacol Ther. 2022 Jan;27:10742484221100107. doi: 10.1177/10742484221100107
- Stankov S, Cuchel M. Gene editing for dyslipidemias: new tools to “cut” lipids. Atherosclerosis. 2023 Mar;368:14–24. doi: 10.1016/j.atherosclerosis.2023.01.010
- Safety and pharmacodynamic effects of VERVE-101. [cited 2024 Jan]. Available from: https://www.vervetx.com/sites/default/files/202311/Verve_AHA_2023_LBS_for%20website.pdf
- Verve therapeutics announces updates on its PCSK9 Program. [3. [2024 Apr]. Available from: https://ir.vervetx.com/news-releases/news-release-details/verve-therapeutics-announces-updates-its-pcsk9-program
- Puccini M, Landmesser U, Rauch U. Pleiotropic effects of PCSK9: focus on thrombosis and haemostasis. Metabolites. [2022 Mar 4];12(3):226. doi: 10.3390/metabo12030226
- Inoue I, Takenaka Y, Kin Y, et al. A sudden onset of severe thrombocytopenia while using evolocumab. Case Rep Hematol. 2020;2020:3281626. doi: 10.1155/2020/3281626
- Wyne KL, Pathak K, Seabra MC, et al. Expression of the VLDL receptor in endothelial cells. Arterioscler Thromb Vasc Biol. 1996 Mar;16(3):407–415. doi: 10.1161/01.ATV.16.3.407
- Chen Y, Zhang J, Cui W, et al. CD36, a signaling receptor and fatty acid transporter that regulates immune cell metabolism and fate. J Exp Med 2022 Jun 6];219(6):20211314. doi: 10.1084/jem.34520211314
- Demers A, Samami S, Lauzier B, et al. PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver. Arterioscler Thromb Vasc Biol. 2015 Dec;35(12):2517–2525. doi: 10.1161/ATVBAHA.115.306032